Loading...
•
Dec 31, 2021
Altimmune Q4 2021 Earnings Report
Altimmune reported financial results for Q4 2021 and provided a corporate update.
Key Takeaways
Altimmune reported a revenue of $3.3 million for the three months ended December 31, 2021, compared to $2.3 million in the same period in 2020. The net loss for the three months ended December 31, 2021 was $23.9 million, or $0.57 net loss per share, compared to $10.6 million in the same period in 2020, or $0.29 net loss per share. The company had cash, cash equivalents, short-term investments and restricted cash totaling $190.3 million at December 31, 2021.
Data readouts from multiple clinical trials expected during the next 6 to 12 months
Strong cash position of $190.3 million as of December 31, 2021
Initiation of the Phase 2 MOMENTUM trial of pemvidutide in obesity expected in the first quarter of 2022
Topline data from the extension trial expected in Q4 2022.
Forward Guidance
Altimmune anticipates value-creating data readouts from multiple clinical trials in the next 12 months and expects to read out their HepTcell trial in the first half of 2023.
Positive Outlook
- Phase 1b nonalcoholic fatty liver disease (NAFLD) trial data readout expected in Q3 2022
- Interim analysis planned to assess changes in body weight after 24 weeks of treatment, with an expected readout in Q4 2022
- Topline data from the extension trial expected in Q4 2022
- Results of a drug-drug interaction trial of pemvidutide expected in the first half of 2022
- Study readout for Phase 2 clinical trial in chronic hepatitis B subjects, with study readout expected H1 2023
Challenges Ahead
- Potential impacts due to crises, including conflicts and wars (like the ongoing conflict in Ukraine) and pandemics (like the COVID-19 pandemic), such as delays in regulatory review, manufacturing and supply chain interruptions, access to clinical sites, enrollment, adverse effects on healthcare systems and disruption of the global economy
- The reliability of the results of studies relating to human safety and possible adverse effects resulting from the administration of the Company’s product candidates
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...